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INTRODUCTION
Hepatocellular carcinoma (HCC) is a common cause of
mortality in cancer patients in Korea, with a death rate of
approximately 21 per 100,000 (1). No treatment modality
has been successful in increasing survival time in patients
with advanced HCC, whereas effective treatments, such as
liver transplantation, surgical resection, and local ablation
therapies, are available for patients with small HCCs (2-6).
Although alpha-fetoprotein (AFP) measurement and ultra-
sonography are useful surveillance tests for detecting HCCs at
a stage at which they may be treated, both tests have limita-
tions: AFP shows low sensitivity and specificity, while the
results of ultrasonography are dependent on the skill of those
performing the examination and on the condition of the
patient.
Inactivation of tumor suppressor genes is important in the
development of cancers, and leads to abnormal proliferation,
transformation, invasion, and metastasis (7). Inactivation of
tumor suppressor genes can occur due to silencing as a result
of methylation of tumor suppressor gene promoters, as well
as genetic mutation, loss of heterozygosity (LOH), or deletion
of homozygosity (8-10).
The tumor suppressor gene p16INK4A is located on chromo-
some 9p21 and encodes the p16 protein, which binds selec-
tively to CDK4 to inhibit activation of the CDK4/cyclin D
complex in G1 phase (11). Recent studies have indicated the
occurrence of structural changes in p16INK4A in HCC (12, 13).
Inactivation of this gene, which normally inhibits progres-
sion to the G1 phase of the cell cycle, is involved in the ini-
tiation of tumors. The methylation of p16INK4A is known to
silence transcription of the gene (14).
The degree of p16INK4A methylation shows a wide range of
variation (from 0 to 94%) in tumor tissues of HCC patients
(8, 15-22), and this change has been detected in the sera of
such patients (20).
This study was performed to evaluate the incidence of
methylated p16INK4A in the sera of liver cirrhosis (LC) and HCC
patients, and to examine its role as a tumor marker of HCC. 
MATERIALS AND METHODS
Subjects
This study included 23 patients with cirrhosis and 46 with
HCC. Cirrhosis patients were selected on the basis of clini-
cal, biochemical, and radiological findings, and follow-up
was performed for at least 6 months to exclude undetected
cancers. HCC patients (23) were selected consecutively from
those diagnosed according to the criteria of the European
association for the study of the liver (EASL) (Table 1).
Methods
Methylation-specific PCR (MSP) (24) was used to detect
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Detection of Aberrant p16
INK4A Methylation in Sera of Patients with
Liver Cirrhosis and Hepatocellular Carcinoma
Hepatocellular carcinomas (HCCs) show genomic alterations, including DNA rear-
rangements associated with HBV DNA integration, loss of heterozygosity, and
chromosomal amplification. The genes most frequently involved are those encod-
ing tumor suppressors. The p16
INK4A tumor suppressor gene frequently displays
genetic alteration in HCC tissues. The present study was performed to examine
the incidence of methylated p16
INK4A in the sera of liver cirrhosis (LC) and HCC
patients, and to evaluate its role as a tumor marker of HCC. The sera of 23 LC
patients and 46 HCC patients were examined in this study. The methylation status
of p16
INK4A was evaluated by methylation-specific PCR of serum samples. Methy-
lated p16
INK4A was detected in 17.4% (4/23) of LC patients and in 47.8% (22/46) of
HCC patients. No association was demonstrated between p16
INK4A methylation
and serum AFP level. As the status of p16
INK4A methylation was not associated with
serum AFP level, it may have a role as a tumor marker of HCC.
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abnormal methylation of the p16
INK4A gene. Serum AFP was
measured by radioimmunoassay (BioSource Europe S.A.,
Nivelles, Belgium). 
Isolation and Quantification of DNA
To obtain serum, blood specimens from each patient were
centrifuged at 3,000 RPM for 20 min. Sera were stored at -70
℃ until DNA extraction. A total volume of 2 mL of serum
was treated with an equal volume of 1% sodium dodecyl
sulfate, 0.5 mg/mL proteinase K (1× SDS/PK) for over 16
hr at 58℃. The solution was extracted twice with an equal
volume of PC-8 [250 mL of Aquaphenol, supplemented with
pH 8.0 buffer (Qbiogene Inc., Carlsbad, CA, U.S.A.), 40 mL
of distilled water, 2.5 mL of 0.5 M EDTA, and 200 mL of
chloroform], and 7.5 M ammonium acetate was added to
the supernatant. After addition of glycogen, the DNA was
precipitated with ethanol. The DNA pellet was washed twice
with 70% ethanol, dried, and dissolved in LoTE (30 mM
Tris-HCl, 0.3 mM EDTA).
Modification Reaction
Bisulfite conversion of genomic DNA was performed using
the reagents provided with a CpGenomeTM DNA modifica-
tion kit, according to the manufacturer’s protocols (Intergen,
Edinburgh, U.K.). The modified DNA was eluted into 20  L
of TE (10 mM Tris-HCl, 1 mM EDTA), and was either used
immediately as a template for MSP or stored at -20℃.
Methylation-specific Polymerase Chain Reaction (MSP)
Bisulfite-modified DNA was amplified using the primers
provided with a CpG WIZTM p16
INK4A amplification kit (Inter-
gen, Edinburgh, U.K.). The PCR mixture contained 1×uni-
versal PCR buffer, dNTPs (each at 0.25 mM), methylated or
unmethylated primer, 1 unit of AmpliTaq Gold polymerase
(Perkin Elmer, Wellesley, MA), and modified DNA (100 ng)
in a final volume of 12.5  L. Water was used as a negative
control, while positive control DNA was supplied with the
kit. Amplification was carried out in a thermal cycler (MWG-
Biotech AG, Ebersberg, Germany) as follows: 94℃for 5 min;
35 cycles of 94℃ for 45 sec, 56℃ for 45 sec, and 72℃ for
1 min; with a final extension of 10 min at 72℃. PCR prod-
ucts (12.5  L) were separated on non-denaturing 10% poly-
acrylamide gels, stained with ethidium bromide, and visu-
alized under UV illumination.
Statistical Analysis
Statistical analysis was performed using the SPSSTM‚ version
11.0 for Windows software (SPSS Inc., Chicago, IL, U.S.A.).
The significance of variations between groups was examined
by chi-square test, Fisher’s exact test, or Student’s t-test.
RESULTS
Clinical Features of Patients
The average age of patients was 57±11 yr (mean standard
deviation), and ranged from 30 to 86. The patient population
consisted of 45 men and 24 women. Forty patients (58.0%)
*Four techniques considered. US, spiral CT, MRI, and angiography.
Cytohistological criteria
Non-invasive criteria (restricted to cirrhotic patients)
1. Radiological criteria: two coincident imaging techniques*
Focal lesion >2 cm with arterial hypervascularization
2. Combined criteria: one imaging technique associated with AFP
Focal lesion >2 cm with arterial hypervascularization
AFP levels >400 ng/mL
Table 1. Diagnostic criteria for hepatocellular carcinoma
*Fisher’s exact test. 
� Student’s t-test.
Liver cirrhosis HCC p value
Number of patients 23 46
Sex (M/F) 13/10 32/14 0.290*
Age (yr) 58±14 56±9 0.624
�
Etiology (%) 0.010*
Chronic hepatitis B 43.5 (10/23) 65.2 (30/46)
Chronic hepatitis C 13.0 (3/23) 21.7 (10/46)
Alcohol 34.8 (8/23) 4.3 (2/46)
Unknown 8.7 (2/23) 10.9 (5/46)
Alpha-fetoprotein (ng/mL) 82.9±197.7 11,327.9±23,485.9 0.003
�
Table 2. Clinical and laboratory features of cirrhosis and HCC
patients
Fig. 1. Detection of aberrant p16
INK4A methylation (sample numbers 14, 38, 39 and 40, as indicated with arrows) in the sera of patients with
liver cirrhosis (LC) and hepatocellular carcinoma (HCC). U, unmethylated; M, methylated; bp, base pairs.
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were positive for HBsAg and 13 (18.8%) were positive for
anti-HCV antibody. The clinical and laboratory features of
each group are shown in Table 2.
Detection of Aberrant p16
INK4A Methylation in Serum
Using MSP
Methylated p16INK4A was detected in 47.8% (22/46) of HCC
patients, a significantly higher rate than the 17.4% (4/23)
seen in LC patients (p=0.014) (Fig. 1).
Sensitivity, Specificity, and Positive Predictive Value of
the Detection of p16
INK4A Methylation in the Diagnosis of
Hepatocellular Carcinoma
Aberrant serum p16INK4A methylation showed 47.8% (22/46)
sensitivity, 82.6% (19/23) specificity, and 84.6% (22/26)
positive predictive value in the diagnosis of HCC.
Association of p16
INK4A Methylation Status and Serum
AFP Level or Tumor Size in Patients with Hepatocellular
Carcinoma
There were no associations between the status of p16INK4A
methylation and serum AFP level in HCC patients (Table 3,
Fig. 2) or tumor size (Table 4).
DISCUSSION
The tumor suppressor gene p16INK4A exhibits variations,
including methylation, that are involved in the process of
carcinogenesis. A causal relationship between genetic varia-
tion and methylation has yet to be determined. Kondo et al.
(8) studied LOH, microsatellite instability, and DNA methy-
lation in HCC and in non-cancerous surrounding tissue by
microdissection. Their results suggested that methylation
often occurs in both tissue types, that it precedes LOH, and
that methylation is involved in the early genesis of HCC as
the cause of LOH. 
The reported rate of incidence of p16INK4A methylation is
quite variable, ranging from 0% to 94% in HCC (8, 15, 22),
and from 29.4% to 83% in cirrhosis (8, 21, 22). This may
be due to the lack of a standardized method of detection and
to the diversity in the clinical courses of patient groups. There
have been few serum studies of p16INK4A methylation in HCC
patients. Wong et al. (20) reported abnormal p16INK4A methy-
lation in 60% of sera and in 73% of tissue in HCC patients.
In the present study, abnormal p16INK4A methylation was
detected in 48% of the sera of HCC patients. Further stud-
ies on plasma or sera are required; large variations in inci-
dence may be expected due to differences in sample materi-
als, detection methods, and/or subjects selected.
Wong et al. (20) reported that p16INK4A methylation was not
detected in the plasma of patients with either liver cirrhosis
or hepatitis, whereas in the present study it was detected in
the sera of 17.4% of cirrhosis patients. We infer that abnor-
mal p16INK4A methylation can also be detected in the sera of
patients with cirrhosis because it is frequently found in non-
tumorous tissues (8). AFP and albumin mRNA were also de-
tected in the sera of hepatitis and cirrhosis patients, as well as
in those of HCC patients (25). More meticulous methods may
be required to detect p16INK4A methylation in cirrhosis patients,
as the amount of circulating DNA is lower in the sera of cir-
rhosis patients than in that of HCC patients. The incidence
of methylated p16INK4A DNA did not differ between small
(≤3 cm) and large HCCs, and was not correlated with AFP
levels in the sera of HCC patients. Wong et al. (26) reported
a significant correlation between the methylation of circulat-
ing DNA and serum AFP levels in HCC patients. There is a
danger in generalizing from this result, however, as that study
included only six cases of HCC without methylation. 
Our study suggested that methylated p16INK4A DNA may
*Two patients were excluded due to long interval between the AFP test
date and serum sampling for methylation. 
� chi-square test.
Methylation (%)
AFP ( g/L) p value
0.690
�
Positive Negative
≥20 (n=28) 67.0 61.0
< 20 (n=16) 33.0 39.0
Table 3. Association between p16
INK4A methylation and serum
AFP levels in patients with HCC*
*Chi-square test.
Methylation (%)
Size (cm) p value
0.226
�
Positive Negative
>3 (n=25) 63.6 45.8
≤3 (n=21) 36.4 54.2
Table 4. Association between p16
INK4A methylation and tumor
size
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Fig. 2. Serum AFP levels of 44 HCC patients according to status
of p16
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play an important role as a tumor marker in detection of
HCC. The state of serum p16INK4A methylation discriminated
HCC from cirrhosis with a sensitivity of 47.8% and a speci-
ficity of 82.6%. As there is no correlation between serum
methylation and AFP, it may be a useful complementary tool
to the AFP test.
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